Clinical Trial Update: Combivent Respimat 1-year Safety Study in Patients With Chronic Obstructive Pulmonary Disease [Phase 3]

View source ↗

Summary

A Phase 3 one-year safety study of Combivent Respimat in chronic obstructive pulmonary disease has completed, with results posted in 2012. The update summarizes…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Combivent Respimat (ipratropium bromide and albuterol sulfate)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 3 | Status: COMPLETED | Results posted: 2012-05-01